PHR1286

Applied Filters:

Keyword:'PHR1286'

Showing 1-30 of 64 results for "PHR1286" within Papers

[Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].

J J de Arriba Méndez et al.

Medicina clinica, 117(7), 278-279 (2001-09-20)

Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Arunava Ghosh et al.

The Journal of biological chemistry, 287(46), 38922-38935 (2012-09-20)

The classical late infantile neuronal ceroid lipofuscinosis (LINCLs) is an autosomal recessive disease, where the defective gene is Cln2, encoding tripeptidyl-peptidase I (TPP1). At the molecular level, LINCL is caused by accumulation of autofluorescent storage materials in neurons and other

Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects.

J-M Nicolas et al.

Drug metabolism and disposition: the biological fate of chemicals, 40(8), 1466-1472 (2012-04-28)

Brivaracetam (BRV) is a new high-affinity synaptic vesicle protein 2A ligand in phase III for epilepsy. Initial studies suggested that the hydroxylation of BRV into BRV-OH is supported by CYP2C8. Other metabolic routes include hydrolysis into a carboxylic acid derivative

Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy.

Bernardino Roca et al.

The Annals of pharmacotherapy, 36(4), 730-731 (2002-04-09)

Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine.

Scott A Hoose et al.

PloS one, 7(5), e36503-e36503 (2012-05-09)

Screening chemical libraries to identify compounds that affect overall cell proliferation is common. However, in most cases, it is not known whether the compounds tested alter the timing of particular cell cycle transitions. Here, we evaluated an FDA-approved drug library

Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins.

Pradeep Sharma et al.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 47(1), 244-255 (2012-04-28)

To support drug development, the drug-drug interaction potential (DDI) of an investigational drug (AZX) was assessed against the probe estradiol 17β-glucuronide as well as against simvastatin acid, atorvastatin, pravastatin, pitavastatin, fluvastatin, rosuvastatin and estrone 3-sulfate. The inhibitory potentials of the

Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.

Mark J Cziraky et al.

Journal of clinical lipidology, 7(2), 102-108 (2013-02-19)

The occurrence of low rates of rhabdomyolysis among patients receiving lipid-lowering drugs (LLDs) in randomized clinical trials may be elucidated with population-based studies. To determine the risk of hospitalized rhabdomyolysis associated with LLD therapy. This observational study used claims data

Summaries for patients. Screening, monitoring, and treatment of early stage chronic kidney disease: recommendations from the American College of Physicians.

Annals of internal medicine, 159(12), I-28 (2013-10-23)

Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.

Toshiyuki Kudo et al.

Drug metabolism and disposition: the biological fate of chemicals, 41(2), 362-371 (2012-11-10)

The plasma concentration of repaglinide is reported to increase greatly when given after repeated oral administration of itraconazole and gemfibrozil. The present study analyzed this interaction based on a physiologically based pharmacokinetic (PBPK) model incorporating inhibition of the hepatic uptake

Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians.

Amir Qaseem et al.

Annals of internal medicine, 159(12), 835-847 (2013-10-23)

The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. This guideline is based on a systematic

A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement.

Faraz Kazmi et al.

Drug metabolism and disposition: the biological fate of chemicals, 43(4), 523-533 (2015-01-18)

Desloratadine (Clarinex), the major active metabolite of loratadine (Claritin), is a nonsedating long-lasting antihistamine that is widely used for the treatment of allergic rhinitis and chronic idiopathic urticaria. For over 20 years, it has remained a mystery as to which

Monitoring and removal of residual phthalate esters and pharmaceuticals in the drinking water of Kaohsiung City, Taiwan.

Gordon C C Yang et al.

Journal of hazardous materials, 277, 53-61 (2014-04-08)

This study monitored the occurrence and removal efficiencies of 8 phthalate esters (PAEs) and 13 pharmaceuticals present in the drinking water of Kaohsiung City, Taiwan. The simultaneous electrocoagulation and electrofiltration (EC/EF) process was used to remove the contaminants. To this

An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver.

Yusuke Ito et al.

Drug metabolism and disposition: the biological fate of chemicals, 42(12), 2109-2116 (2014-09-14)

Probenecid, a widely used uricosuric agent, is mainly metabolized to probenecid acyl glucuronide (PRAG), which is considered a causal substance of severe allergic or anaphylactoid reactions. PRAG can be hydrolyzed (deglucuronidated) to probenecid. The purpose of this study was to

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Christina L Aquilante et al.

British journal of clinical pharmacology, 75(1), 217-226 (2012-05-26)

The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate). In this randomized, two phase crossover study, 30 healthy Caucasian

[Gemfibrozil: new aspects in clinical use].

N Tada

Nihon rinsho. Japanese journal of clinical medicine, 59 Suppl 3, 625-630 (2001-05-12)

CCR5 controls immune and metabolic functions during Toxoplasma gondii infection.

Giuliano Bonfá et al.

PloS one, 9(8), e104736-e104736 (2014-08-15)

CCR5, an important receptor related to cell recruitment and inflammation, is expressed during experimental Toxoplasma gondii infection. However, its role in the immunopathology of toxoplasmosis is not clearly defined yet. Thus, we inoculated WT and CCR5(-/-) mice with a sub

Effects of chronic, parental pharmaceutical exposure on zebrafish (Danio rerio) offspring.

Michal Galus et al.

Aquatic toxicology (Amsterdam, Netherlands), 151, 124-134 (2014-02-15)

In this study we explored how parental exposure to pharmaceuticals influences reproduction in offspring. Adult zebrafish (Danio rerio) were exposed for 6 weeks to 10 μgL(-1) of carbamazepine (CBZ) and gemfibrozil (GEM), two commonly prescribed drugs. Embryos were collected, reared

Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense.

Grant T Corbett et al.

Journal of immunology (Baltimore, Md. : 1950), 189(2), 1002-1013 (2012-06-19)

Chronic inflammation is becoming a hallmark of several neurodegenerative disorders and accordingly, IL-1β, a proinflammatory cytokine, is implicated in the pathogenesis of neurodegenerative diseases. Although IL-1β binds to its high-affinity receptor, IL-1R, and upregulates proinflammatory signaling pathways, IL-1R antagonist (IL-1Ra)

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.

C M Spencer et al.

Drugs, 51(6), 982-1018 (1996-06-01)

Gemfibrozil improves lipid and apolipoprotein profiles, particularly very low density lipoprotein (VLDL) triglyceride and high density lipoprotein (HDL) cholesterol levels, in patients with dyslipidaemia when administered at a total daily dose of 900 or 1200 mg. As demonstrated by the

Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas).

Sarah Y Skolness et al.

Environmental toxicology and chemistry, 31(11), 2615-2624 (2012-08-23)

Fibrates are a class of pharmaceuticals that indirectly modulate cholesterol biosynthesis through effects on peroxisome proliferator-activated receptors. Gemfibrozil is a fibrate that has been detected in wastewater treatment plant influents, effluents, and drinking water. The objective of the present study

Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.

Monica A Muñoz et al.

Journal of acquired immune deficiency syndromes (1999), 64(3), 254-260 (2013-07-31)

The goal of this study was to compare the effectiveness of fish oil, fenofibrate, gemfibrozil, and atorvastatin on reducing triglyceride (TG) levels among a large cohort of HIV-infected patients in clinical care. Retrospective observational cohort study. The primary endpoint was

Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions.

Anna Vildhede et al.

Drug metabolism and disposition: the biological fate of chemicals, 42(7), 1210-1218 (2014-05-07)

Differences in the expression and function of the organic anion transporting polypeptide (OATP) transporters contribute to interindividual variability in atorvastatin clearance. However, the importance of the bile acid transporter sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1) in atorvastatin uptake clearance (CLupt)

Validated spectrofluorometric method for determination of gemfibrozil in self nanoemulsifying drug delivery systems (SNEDDS).

Ana M Sierra Villar et al.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 113, 22-27 (2013-05-28)

A spectrofluorometric method has been developed and validated for the determination of gemfibrozil. The method is based on the excitation and emission capacities of gemfibrozil with excitation and emission wavelengths of 276 and 304 nm respectively. This method allows de

Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation.

Chin Fung Kelvin Kan et al.

Journal of lipid research, 55(8), 1657-1667 (2014-06-01)

ACSL4 is a member of the long-chain acyl-CoA synthetase (ACSL) family with a marked preference for arachidonic acid (AA) as its substrate. Although an association between elevated levels of ACSL4 and hepatosteatosis has been reported, the function of ACSL4 in

Pharmaceuticals in the freshwater invertebrate, Gammarus pulex, determined using pulverised liquid extraction, solid phase extraction and liquid chromatography-tandem mass spectrometry.

Thomas H Miller et al.

The Science of the total environment, 511, 153-160 (2014-12-30)

The development, characterisation and application of a new analytical method for multi-residue PPCP determination in the freshwater amphipod, Gammarus pulex are presented. Analysis was performed using pulverised liquid extraction (PuLE), solid phase extraction (SPE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Occurrence and distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine environment: influence of hydrodynamics and physical-chemical properties.

Stéphane Bayen et al.

Environmental pollution (Barking, Essex : 1987), 182, 1-8 (2013-07-31)

The fate and exposure risks of pharmaceutically active compounds (PhACs) and endocrine disrupting chemicals (EDCs) in marine environments are not well-understood. In this study we developed a multi-residue analytical method for quantifying concentrations of forty target compounds in seawater from

Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes.

Norimasa Jinno et al.

Xenobiotica; the fate of foreign compounds in biological systems, 44(8), 677-686 (2014-03-01)

1. In order to evaluate the inhibition activity of 1-aminobenzotriazole (ABT) and (-)-borneol (borneol) against cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT), the substrates of these metabolic enzymes were incubated with ABT and borneol in human hepatocytes. We found that 3 mM ABT

Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action.

Gianluca Miglio et al.

British journal of pharmacology, 167(3), 641-653 (2012-05-19)

Peroxisome proliferator-activated receptor (PPAR) agonists exert anti-albuminuric effects. However, the nephroprotective effects of these drugs remain to be fully understood. We have investigated whether gemfibrozil, GW0742 and pioglitazone protect human podocytes against nutrient deprivation (ND)-induced cell death and the role

Ionization suppression effects with condensed phase membrane introduction mass spectrometry: methods to increase the linear dynamic range and sensitivity.

Kyle D Duncan et al.

Journal of mass spectrometry : JMS, 50(3), 437-443 (2015-03-25)

Condensed phase membrane introduction mass spectrometry (CP-MIMS) is an online analytical method that allows for the direct, trace level measurement of a wide range of analytes in complex samples. The technique employs a semi-permeable membrane that transfers analytes from a

Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.

R Preston Mason et al.

Biochimica et biophysica acta, 1848(2), 502-509 (2014-12-03)

Lipid oxidation leads to endothelial dysfunction, inflammation, and foam cell formation during atherogenesis. Glucose also contributes to lipid oxidation and promotes pathologic changes in membrane structural organization, including the development of cholesterol crystalline domains. In this study, we tested the

Page 1 of 3